| payload |
{"created_at":"2026-04-03T11:12:58.166 {"created_at":"2026-04-03T11:12:58.166696+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:753b94cf238f6c45","evidence_event_ids":["evt_05fe91dab30a"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/706698/0001096906-26-000477.txt","as_of":"2026-04-03T11:12:58.166696+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/706698/0001096906-26-000477.txt","company":"UTAH MEDICAL PRODUCTS INC","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/706698/0001096906-26-000477.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_b5b5308b0726b06f","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/706698/0001096906-26-000477.txt","content_type":"text/plain","enriched_at":"2026-04-03T14:09:37.810973+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"proxy statement","final_url":"https://www.sec.gov/Archives/edgar/data/706698/0001096906-26-000477.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/706698/0001096906-26-000477.txt","source_event_id":"evt_05fe91dab30a","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEF 14A","fp":"aaab461e7e32c9a9","kind":"sec_filing","published_at":"20260402","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":1.0,"dates_mentioned":["2026-04-02","2026-05-01","2026-03-02"],"entities":[{"asset_class":"equity","name":"Utah Medical Products Inc.","relevance":"issuer","symbol":"UTMD","type":"company"}],"event_type":"listing","information_gaps":["No specific details on the directors being nominated or the executive compensation program changes."],"key_facts":["Annual Meeting scheduled for May 1, 2026, at 12:00 noon Mountain time.","Proposals include electing two directors, ratifying Haynie & Company as the accounting firm, and an advisory vote on executive compensation.","Only stockholders of record as of March 2, 2026, can vote."],"numeric_claims":[],"primary_claim":"UTMD filed a DEF 14A proxy statement on April 2, 2026.","relevance_score":0.8,"sentiment":"neutral","source_quality":"high","summary":"Utah Medical Products Inc. (UTMD) filed a DEF 14A proxy statement for its 2026 Annual Meeting, scheduled for May 1, 2026, to elect two directors, ratify an accounting firm, and hold an advisory vote on executive compensation.","topics":["proxy statement","annual meeting","corporate governance"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEF 14A \u00b7 UTAH MEDICAL PRODUCTS INC \u00b7 Filed 20260402","ticker":"UTMD","tickers":["UTMD"],"title":"UTMD filed DEF 14A","url":"https://www.sec.gov/Archives/edgar/data/706698/0001096906-26-000477.txt"}}... |